Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Picard Medical (PMI) Net Income (2024 - 2026)

Picard Medical posted quarterly Net Income of -$7.6 million for Q1 2026, down 36.95% year-on-year from -$12.1 million in Q1 2025, and down 133.53% on a QoQ basis from $22.7 million in Q4 2025.

Picard Medical (PMI) has 3 years of Net Income data on file, last reported at -$7.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income fell 36.95% year-over-year to -$7.6 million; the trailing twelve-month figure through Mar 2026 stood at -$2.1 million (up 91.67% YoY), and the FY2024 full-year result was -$21.1 million, changed N/A from the prior year.
  • Net Income for Q1 2026 stood at -$7.6 million, down from $22.7 million in the prior quarter.
  • Across five years, Net Income topped out at $22.7 million in Q4 2025 and bottomed at -$10.4 million in Q3 2025.
  • The 3-year median for Net Income is -$6.5 million (2024), against an average of -$3.3 million.
  • Peak annual rise in Net Income reached 356.97% in 2025, while the deepest fall reached 68.0% in 2025.
  • A 3-year view of Net Income shows it stood at -$8.8 million in 2024, then jumped by 356.97% to $22.7 million in 2025, then slumped by 133.53% to -$7.6 million in 2026.
  • The last three Net Income figures came in at -$7.6 million (Q1 2026), $22.7 million (Q4 2025), and -$10.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.08 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 745.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 1.15 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 1.34 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 273.95 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 199.50 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 411.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Picard Medical 12.10 Mn 12.10 Mn 275,000.00 -7.62 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -7.62 Mn
Dec 31, 2025 -4.33 Mn
Sep 30, 2025 -10.43 Mn
Jun 30, 2025 -6.72 Mn
Dec 31, 2024 -8.34 Mn
Sep 30, 2024 -6.21 Mn
Jun 30, 2024 -4.06 Mn